Cutting Edge: Predetermined Avidity of Human CD8 T Cells Expanded on Calibrated MHC/Anti-CD28-Coated Microspheres 1

Cytotoxic CD8 T cells are key effectors in the immunotherapy of malignant and viral diseases. However, the lack of efficient methods for their in vitro priming and expansion has become a bottleneck to the development of vaccines and adoptive transfer strategies. Synthetic artificial APCs (aAPCs) are now emerging as an attractive tool for eliciting and expanding CTL responses. We show that, by controlling the MHC density on aAPCs, high- or low-avidity tumor-directed human CTL lines can be raised effectively in vitro if costimulation via CD28 and IL-12 is provided. Compared with low-avidity CTL lines, high-avidity CTLs need 100- to 1000-fold less peptide for activation, bind more MHC tetramers, and, as expected, are superior in recognizing tumor cell lines expressing Ag. We believe that the possibility to raise Ag-specific T cells with predetermined avidity will be crucial for the future use of aAPCs in immunotherapeutical settings.

[1]  H. Rammensee,et al.  Human platelets express heat shock protein receptors and regulate dendritic cell maturation. , 2002, Blood.

[2]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[3]  V. Cerundolo,et al.  Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC1 , 2001, The Journal of Immunology.

[4]  H. Müller-Eberhard,et al.  Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Speiser,et al.  High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals , 1999, The Journal of experimental medicine.

[6]  C. Wilson,et al.  HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. , 1999, Journal of immunology.

[7]  Michel Sadelain,et al.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells , 2000, Nature Biotechnology.

[8]  M. Mescher,et al.  Cell-sized, supported artificial membranes (pseudocytes): response of precursor cytotoxic T lymphocytes to class I MHC proteins. , 1986, Journal of immunology.

[9]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Speiser,et al.  Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR1 , 2002, The Journal of Immunology.

[11]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Kourilsky,et al.  In vitro induction of naive cytotoxic T lymphocytes with complexes of peptide and recombinant MHC class I molecules coated onto beads: role of TCR/ligand density , 1998, European journal of immunology.

[13]  M R Jackson,et al.  Requirements for stimulating naive CD8+ T cells via signal 1 alone. , 1998, Journal of immunology.

[14]  M. Davis,et al.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. , 1999, Journal of immunology.

[15]  A. Mackensen,et al.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells , 2003, Nature Medicine.

[16]  M. Jenkins,et al.  Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. , 1999, Journal of immunology.

[17]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[18]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.